An off-site meeting of the Committee for Social and Cultural Development of the Majilis of the Parliament of the Republic of Kazakhstan on "Prospects for the Development of the Pharmaceutical Industry" was held at the premises of SK-Pharmacia LLC in Astana. The meeting focused on pressing issues related to the pharmaceutical industry and the provision of medicines to the population.
Opening the meeting, Committee Chairman Askhat Aimagambetov noted the importance of systematically developing the domestic pharmaceutical industry, expanding localization of production, and improving the availability of modern medicines for the population.
"Kazakhstan's pharmaceutical industry is demonstrating sustainable growth, strengthening its production and investment potential, expanding localization, and laying the foundation for further reducing import dependence and developing export-oriented production," noted Vice Minister of Health Timur Muratov in his report.
By the end of 2025, pharmaceutical production in Kazakhstan amounted to 191.1 billion tenge, an 8.7% increase compared to the previous year. Investment in the industry reached $142.8 million, and pharmaceutical exports increased to $84 million.
Currently, there are 209 registered domestic manufacturers in the country, including 43 pharmaceutical manufacturers and 166 medical device manufacturers. The share of Kazakhstani manufacturers in volume terms has reached 39.8%, as confirmed by data from the drug labeling and traceability system.
The Vice Minister emphasized that long-term contracts and investment agreements remain key mechanisms for supporting the industry.
As of early 2026, 83 long-term contracts were in effect with 31 Kazakhstani manufacturers for the supply of over 2,000 types of medicines and medical devices. Since December 2025, seven investment agreements have been signed, totaling approximately 360 billion tenge. The implementation of these projects will enable the production of 474 new products, create over 1,140 jobs, and expand the export potential of the domestic pharmaceutical industry.
The meeting focused on improving the drug regulatory system.
In February 2026, Kazakhstan became the first CIS country to achieve Level 3 maturity for its national drug regulatory system, as assessed by the World Health Organization.
Furthermore, to reduce drug registration timelines, a pilot project, "Composite Service," is being implemented using a one-stop-shop approach. This has resulted in a more than halved registration time—from 210 to 100 days. For drugs from countries with high regulatory standards, an accelerated registration procedure of 15 days has been introduced.
"Implementing this project will provide the population with faster access to modern drugs, reduce the administrative burden on the state, and create a predictable environment for businesses," stated Timur Muratov.
The Vice Minister also reported on the introduction of drug labeling, which enables full traceability down to the patient level and improves the effectiveness of state oversight and regulation.
In the final part of his report, Timur Muratov outlined ongoing measures aimed at enhancing the potential of Kazakhstan's pharmaceutical and medical industries, including stimulating the localization of drug and medical device production and developing a comprehensive and effective pharmaceutical policy.
Источник: Казахстанский Фармацевтический Вестник, pharmnews.kz
Opening the meeting, Committee Chairman Askhat Aimagambetov noted the importance of systematically developing the domestic pharmaceutical industry, expanding localization of production, and improving the availability of modern medicines for the population.
"Kazakhstan's pharmaceutical industry is demonstrating sustainable growth, strengthening its production and investment potential, expanding localization, and laying the foundation for further reducing import dependence and developing export-oriented production," noted Vice Minister of Health Timur Muratov in his report.
By the end of 2025, pharmaceutical production in Kazakhstan amounted to 191.1 billion tenge, an 8.7% increase compared to the previous year. Investment in the industry reached $142.8 million, and pharmaceutical exports increased to $84 million.
Currently, there are 209 registered domestic manufacturers in the country, including 43 pharmaceutical manufacturers and 166 medical device manufacturers. The share of Kazakhstani manufacturers in volume terms has reached 39.8%, as confirmed by data from the drug labeling and traceability system.
The Vice Minister emphasized that long-term contracts and investment agreements remain key mechanisms for supporting the industry.
As of early 2026, 83 long-term contracts were in effect with 31 Kazakhstani manufacturers for the supply of over 2,000 types of medicines and medical devices. Since December 2025, seven investment agreements have been signed, totaling approximately 360 billion tenge. The implementation of these projects will enable the production of 474 new products, create over 1,140 jobs, and expand the export potential of the domestic pharmaceutical industry.
The meeting focused on improving the drug regulatory system.
In February 2026, Kazakhstan became the first CIS country to achieve Level 3 maturity for its national drug regulatory system, as assessed by the World Health Organization.
Furthermore, to reduce drug registration timelines, a pilot project, "Composite Service," is being implemented using a one-stop-shop approach. This has resulted in a more than halved registration time—from 210 to 100 days. For drugs from countries with high regulatory standards, an accelerated registration procedure of 15 days has been introduced.
"Implementing this project will provide the population with faster access to modern drugs, reduce the administrative burden on the state, and create a predictable environment for businesses," stated Timur Muratov.
The Vice Minister also reported on the introduction of drug labeling, which enables full traceability down to the patient level and improves the effectiveness of state oversight and regulation.
In the final part of his report, Timur Muratov outlined ongoing measures aimed at enhancing the potential of Kazakhstan's pharmaceutical and medical industries, including stimulating the localization of drug and medical device production and developing a comprehensive and effective pharmaceutical policy.
Источник: Казахстанский Фармацевтический Вестник, pharmnews.kz
